who s developing what in global biopharmaceuticals...september 2008 ©espicom business intelligence...
TRANSCRIPT
World Leaders in Health Industry Analysis
Who’s Developing What in global biopharmaceuticals?
©Espicom Business Intelligence iiiSeptember 2008
Who’s Developing What in Global Biopharmaceuticals? Table of Contents
ContentsAffymAx........................................................................................................................................................ 1
Key Personnel ............................................................................................................................................................................ 1Company Overview .................................................................................................................................................................. 1Milestones .................................................................................................................................................................................. 2R&D Pipeline .............................................................................................................................................................................. 3
Affymax R&D Pipeline, August 2008 .....................................................................................................................................................................................................3Haematology..........................................................................................................................................................................3
Hematide .............................................................................................................................................................................................3Other.Indications....................................................................................................................................................................4
Innotide ................................................................................................................................................................................................4Adeptide ..............................................................................................................................................................................................5Angiotide .............................................................................................................................................................................................5
Technology ................................................................................................................................................................................ 5Agreements ............................................................................................................................................................................... 6
Takeda.....................................................................................................................................................................................6Entremed.................................................................................................................................................................................7Nektar......................................................................................................................................................................................7
Key Financial Data .................................................................................................................................................................... 8Appraisal & Evaluation ............................................................................................................................................................. 8
Platform,.Pipeline,.Products.................................................................................................................................................8Corporate.Environment.........................................................................................................................................................8
AmbIT.bIOsCIENCEs...................................................................................................................................... 9Key Personnel ............................................................................................................................................................................ 9Company Overview .................................................................................................................................................................. 9Milestones ................................................................................................................................................................................ 10R&D Pipeline ............................................................................................................................................................................ 10
Ambit Biosciences R&D Pipeline, August 2008 ....................................................................................................................................................................................10Oncology...............................................................................................................................................................................10
AC220 ..................................................................................................................................................................................................10AC480 .................................................................................................................................................................................................11AURORA Kinase Inhibitors ..............................................................................................................................................................11BRAF Kinase Inhibitors ....................................................................................................................................................................11JAK2 ....................................................................................................................................................................................................11ABL (T3 151) .......................................................................................................................................................................................11
Technologies............................................................................................................................................................................ 11Kinase.Profiling.Platform....................................................................................................................................................11
Agreements ............................................................................................................................................................................. 12Cephalon...............................................................................................................................................................................12bristol-myers.squibb...........................................................................................................................................................12medarex................................................................................................................................................................................12AstraZeneca..........................................................................................................................................................................12GlaxosmithKline...................................................................................................................................................................13Roche.....................................................................................................................................................................................13Pfizer......................................................................................................................................................................................13
Key Financial Data .................................................................................................................................................................. 13Appraisal & Evaluation ........................................................................................................................................................... 13
Platform,.Pipeline,.Products...............................................................................................................................................13Corporate.Environment.......................................................................................................................................................13
AmbRx.......................................................................................................................................................... 15
©Espicom Business Intelligence September 2008iv
Who’s Developing What in Global Biopharmaceuticals?
Key Personnel .......................................................................................................................................................................... 15Company Overview ................................................................................................................................................................ 15Milestones ................................................................................................................................................................................ 16R&D Pipeline ............................................................................................................................................................................ 16
Human.Growth.Hormone....................................................................................................................................................16ARX201 ...............................................................................................................................................................................................16
Technologies............................................................................................................................................................................ 16ReCODE.Technology.............................................................................................................................................................16
Patents ...................................................................................................................................................................................... 17Agreements ............................................................................................................................................................................. 17
merck.serono........................................................................................................................................................................17Eli.Lilly....................................................................................................................................................................................17Roche.....................................................................................................................................................................................18merck.&.Co............................................................................................................................................................................18
Key Financial Data .................................................................................................................................................................. 18Appraisal & Evaluation ........................................................................................................................................................... 18
Platform,.Pipeline,.Products...............................................................................................................................................18Corporate.Environment.......................................................................................................................................................18
AmyLIN.PHARmACEuTICALs...................................................................................................................... 19Key Personnel .......................................................................................................................................................................... 19Company Overview ................................................................................................................................................................ 19Milestones ................................................................................................................................................................................ 20Marketed Products .................................................................................................................................................................22
metabolism.......................................................................................................................................................................... 22BYETTA (exenatide, AC2993 (synthetic exendin-4)) injection .................................................................................................22SYMLIN (pramlintide acetate) injection .......................................................................................................................................22
R&D Pipeline ............................................................................................................................................................................23Amylin Pharmaceuticals R&D Pipeline, August 2008 ..........................................................................................................................................................................23
metabolism.......................................................................................................................................................................... 23Diabetes .............................................................................................................................................................................................23Obesity ...............................................................................................................................................................................................25
Discontinued Products .......................................................................................................................................................... 27Cardiology.............................................................................................................................................................................27
AC3056 ...............................................................................................................................................................................................27AC2592 ...............................................................................................................................................................................................27
Agreements .............................................................................................................................................................................28Eli.Lilly................................................................................................................................................................................... 28Alkermes............................................................................................................................................................................... 29Nastech................................................................................................................................................................................. 29PsychoGenics....................................................................................................................................................................... 29Kelaroo................................................................................................................................................................................. 29bioseek................................................................................................................................................................................. 30xenome................................................................................................................................................................................ 30Johnson.&.Johnson............................................................................................................................................................. 30Aventis...................................................................................................................................................................................31
Key Financial Data .................................................................................................................................................................. 31Appraisal & Evaluation ........................................................................................................................................................... 32
Platform,.Pipeline,.Products...............................................................................................................................................32Corporate.Environment.......................................................................................................................................................32
ARANA.THERAPEuTICs................................................................................................................................ 33Key Personnel .......................................................................................................................................................................... 33
Table of Contents
©Espicom Business Intelligence vSeptember 2008
Who’s Developing What in Global Biopharmaceuticals?
Company Overview ................................................................................................................................................................ 33Milestones ................................................................................................................................................................................34R&D Pipeline ............................................................................................................................................................................34
Arana Therapeutics R&D Pipeline, August 2008 .................................................................................................................................................................................34Autoimmune.and.Inflammatory.Diseases.........................................................................................................................35
ART621 ................................................................................................................................................................................................35PMX53 ................................................................................................................................................................................................35
Oncology...............................................................................................................................................................................35ART104 ...............................................................................................................................................................................................35ART010................................................................................................................................................................................................36ART150 ...............................................................................................................................................................................................36ART140 ...............................................................................................................................................................................................36ART101................................................................................................................................................................................................36ART160 ...............................................................................................................................................................................................36
Technologies............................................................................................................................................................................ 37Protein.Engineering.Platforms...........................................................................................................................................37
Patents ...................................................................................................................................................................................... 37Patent Families – Revenue Generating ...............................................................................................................................................................................................38Patent Families – Product Development .............................................................................................................................................................................................38
Agreements .............................................................................................................................................................................38Vegenics............................................................................................................................................................................... 38AVEO.Pharmaceuticals........................................................................................................................................................ 38CsL.Limited.......................................................................................................................................................................... 39GlaxosmithKline.................................................................................................................................................................. 39Centocor............................................................................................................................................................................... 39Abbott.................................................................................................................................................................................. 39EvoGenix.Pty........................................................................................................................................................................ 39Kyowa.Hakko....................................................................................................................................................................... 40greenovation.biotech......................................................................................................................................................... 40
Key Financial Data .................................................................................................................................................................. 41Appraisal & Evaluation ........................................................................................................................................................... 41
Platform,.Pipeline,.Products...............................................................................................................................................41Corporate.Environment...................................................................................................................................................... 42
ARCA.bIOPHARmA....................................................................................................................................... 43Key Personnel .......................................................................................................................................................................... 43Company Overview ................................................................................................................................................................ 43Milestones ................................................................................................................................................................................44R&D Pipeline ............................................................................................................................................................................44
Cardiology............................................................................................................................................................................ 44Bucindolol ..........................................................................................................................................................................................44
Agreements ............................................................................................................................................................................. 45Laboratory.Corporation.of.America.Holdings.................................................................................................................. 45
Key Financial Data .................................................................................................................................................................. 45Appraisal & Evaluation ...........................................................................................................................................................46
Platform,.Pipeline,.Products.............................................................................................................................................. 46Corporate.Environment...................................................................................................................................................... 46
ARIus.REsEARCH......................................................................................................................................... 47Key Personnel .......................................................................................................................................................................... 47Company Overview ................................................................................................................................................................ 47Milestones ................................................................................................................................................................................48R&D Pipeline ............................................................................................................................................................................48
Table of Contents
©Espicom Business Intelligence September 2008vi
Who’s Developing What in Global Biopharmaceuticals?
ARIUS Research R&D Pipeline, August 2008 ........................................................................................................................................................................................48Oncology.............................................................................................................................................................................. 49
CD44 Cancer Stem Cell Program/ARH460-16-2 ..........................................................................................................................49Trop-2 Signal Transduction Program/AR47A6.4.2. ....................................................................................................................50CD59 Complement Inhibitor Program/AR36A36.11.1 ...............................................................................................................50CD9 Cancer Stem Cell Program/AR40A746.2.3...........................................................................................................................51AR7BD-33-11A ..................................................................................................................................................................................51Others .................................................................................................................................................................................................51
Technologies............................................................................................................................................................................ 51Patents ...................................................................................................................................................................................... 52Agreements ............................................................................................................................................................................. 52
Centro.de.Immunologia.molecular.(CImAb)......................................................................................................................52xerion.Pharmaceuticals.AG.................................................................................................................................................52PDL.bioPharma.....................................................................................................................................................................53medarex.................................................................................................................................................................................53Oxford.biomedica.................................................................................................................................................................53Genentech.............................................................................................................................................................................53Takeda...................................................................................................................................................................................53
Key Financial Data ..................................................................................................................................................................54Appraisal & Evaluation ...........................................................................................................................................................54
Platform,.Pipeline,.Products.............................................................................................................................................. 54Corporate.Environment...................................................................................................................................................... 54
ARyx.THERAPEuTICs................................................................................................................................... 55Key Personnel .......................................................................................................................................................................... 55Company Overview ................................................................................................................................................................ 55Milestones ................................................................................................................................................................................56R&D Pipeline ............................................................................................................................................................................56
ARYx Therapeutics R&D Pipeline, August 2008 ...................................................................................................................................................................................56Gastrointestinal....................................................................................................................................................................57
ATI-7505 .............................................................................................................................................................................................57ATI-24,000 ..........................................................................................................................................................................................57
Cardiology............................................................................................................................................................................ 58ATI-5923 .............................................................................................................................................................................................58ATI-2042 .............................................................................................................................................................................................58
Antipsychotic....................................................................................................................................................................... 58ATI-9242 .............................................................................................................................................................................................58
metabolism.......................................................................................................................................................................... 59ATI-20,000 ..........................................................................................................................................................................................59
Technologies............................................................................................................................................................................ 59Drug.Design.Technology.................................................................................................................................................... 59
Design and Synthesis of Ideal Metabolites .................................................................................................................................59RetroMetabolic Engineering ..........................................................................................................................................................59Evaluation of Metabolism ..............................................................................................................................................................59
Patents ......................................................................................................................................................................................60Agreements .............................................................................................................................................................................60
Procter.&.Gamble................................................................................................................................................................ 60Key Financial Data .................................................................................................................................................................. 61Appraisal & Evaluation ........................................................................................................................................................... 61
Platform,.Pipeline,.Products...............................................................................................................................................61Corporate.Environment...................................................................................................................................................... 62
AsTEx.THERAPEuTICs................................................................................................................................. 63
Table of Contents
©Espicom Business Intelligence viiSeptember 2008
Who’s Developing What in Global Biopharmaceuticals?
Key Personnel .......................................................................................................................................................................... 63Company Overview ................................................................................................................................................................ 63Milestones ................................................................................................................................................................................64R&D Pipeline ............................................................................................................................................................................ 65
Astex Therapeutics R&D Pipeline, August 2008 ...................................................................................................................................................................................65Oncology.............................................................................................................................................................................. 65
AT7519 ................................................................................................................................................................................................65AT9283 ................................................................................................................................................................................................66AT9311 ................................................................................................................................................................................................66AT13387 ..............................................................................................................................................................................................66AT13148 .............................................................................................................................................................................................67
Technologies............................................................................................................................................................................ 67Drug.Discovery.Platform.....................................................................................................................................................67
PYRAMID ............................................................................................................................................................................................67Patents ...................................................................................................................................................................................... 67Agreements .............................................................................................................................................................................68
Technology........................................................................................................................................................................... 68Cambridge Crystallographic Data Centre ...................................................................................................................................68Daresbury Analytical Research and Technology Service .........................................................................................................68Global Phasing .................................................................................................................................................................................68Rigaku/MSC ......................................................................................................................................................................................68Daylight Chemical Information Systems .....................................................................................................................................69Maybridge .........................................................................................................................................................................................69
Product................................................................................................................................................................................. 69Janssen Research Foundation .......................................................................................................................................................69Aventis ................................................................................................................................................................................................69Mitsubishi Pharma ..........................................................................................................................................................................69AstraZeneca ......................................................................................................................................................................................70Institute of Cancer Research and Cancer Research Technology .............................................................................................70The Wellcome Trust, the Institute of Cancer Research, Cancer Research Technology and GlaxoSmithKline ................71Schering AG ......................................................................................................................................................................................71Fujisawa Pharmaceutical ...............................................................................................................................................................72Boehringer Ingelheim ....................................................................................................................................................................72Novartis ..............................................................................................................................................................................................72Pfizer ...................................................................................................................................................................................................72University of Newcastle upon Tyne/Cancer Research Technology .........................................................................................73GlaxoSmithKline ...............................................................................................................................................................................73Janssen Pharmaceutica ..................................................................................................................................................................73
Key Financial Data .................................................................................................................................................................. 73Appraisal & Evaluation ........................................................................................................................................................... 73
Platform,.Pipeline,.Products.............................................................................................................................................. 73Corporate.Environment.......................................................................................................................................................74
bIOVEx.......................................................................................................................................................... 75Key Personnel .......................................................................................................................................................................... 75Company Overview ................................................................................................................................................................ 75Milestones ................................................................................................................................................................................ 76R&D Pipeline ............................................................................................................................................................................77
BioVex R&D Pipeline, August 2008 ......................................................................................................................................................................................................77Oncology.............................................................................................................................................................................. 77
OncoVEX GM-CSF .............................................................................................................................................................................77Virology................................................................................................................................................................................ 78
Table of Contents
©Espicom Business Intelligence September 2008viii
Who’s Developing What in Global Biopharmaceuticals?
ImmunoVEXHSV2 .............................................................................................................................................................................78Patents ...................................................................................................................................................................................... 78Agreements ............................................................................................................................................................................. 78
Wyeth.Pharmaceuticals...................................................................................................................................................... 78merck.&.Co........................................................................................................................................................................... 78National.Institutes.of.Health.............................................................................................................................................. 78
Key Financial Data .................................................................................................................................................................. 79Appraisal & Evaluation ........................................................................................................................................................... 79
Platform,.Pipeline,.Products.............................................................................................................................................. 79Corporate.Environment...................................................................................................................................................... 80
bIOxELL........................................................................................................................................................ 81Key Personnel .......................................................................................................................................................................... 81Company Overview ................................................................................................................................................................ 81Milestones ................................................................................................................................................................................82R&D Pipeline ............................................................................................................................................................................82
BioXell R&D Pipeline, August 2008 ......................................................................................................................................................................................................82urology................................................................................................................................................................................. 83
BXL628/Elocalcitol ...........................................................................................................................................................................83Pain.Relief............................................................................................................................................................................ 83
MNAC13 ..............................................................................................................................................................................................83musculoskeletal................................................................................................................................................................... 83
BXL093 ................................................................................................................................................................................................83Inflammation....................................................................................................................................................................... 84
TREM-1................................................................................................................................................................................................84TREM Programme ............................................................................................................................................................................84BXL746 ................................................................................................................................................................................................84
Technologies............................................................................................................................................................................84The.VD3.platform................................................................................................................................................................ 84mNAC13.Platform................................................................................................................................................................ 84The.TREm.platform.............................................................................................................................................................. 85
Agreements .............................................................................................................................................................................85Roche.................................................................................................................................................................................... 85Lay.Line.Genomics............................................................................................................................................................... 85merck.&.Co........................................................................................................................................................................... 85Galapagos/Proskelia........................................................................................................................................................... 86Zambon................................................................................................................................................................................ 86
Key Financial Data .................................................................................................................................................................. 87Appraisal & Evaluation ........................................................................................................................................................... 87
Platform,.Pipeline,.Products.............................................................................................................................................. 87Corporate.Environment...................................................................................................................................................... 88
bRuIN.PHARmACEuTICALs......................................................................................................................... 89Key Personnel ..........................................................................................................................................................................89Company Overview ................................................................................................................................................................89R&D Pipeline ............................................................................................................................................................................90
Cardiology............................................................................................................................................................................ 90D-4F ....................................................................................................................................................................................................90
Key Financial Data ..................................................................................................................................................................90Appraisal & Evaluation ...........................................................................................................................................................90
Platform,.Pipeline,.Products.............................................................................................................................................. 90Corporate.Environment.......................................................................................................................................................91
CELLECTIs..................................................................................................................................................... 93
Table of Contents
©Espicom Business Intelligence ixSeptember 2008
Who’s Developing What in Global Biopharmaceuticals?
Key Personnel .......................................................................................................................................................................... 93Company Overview ................................................................................................................................................................ 93Milestones ................................................................................................................................................................................94R&D Pipeline ............................................................................................................................................................................94
Oncology.............................................................................................................................................................................. 95Meganucleases targeting p53 .......................................................................................................................................................95Meganucleases targeting XPC .......................................................................................................................................................95
Immunology........................................................................................................................................................................ 95Meganuclease targeting IL2RG .....................................................................................................................................................95Meganuclease targeting RAG1 ......................................................................................................................................................96
Patents ......................................................................................................................................................................................96Agreements ............................................................................................................................................................................. 97
Artemis.Pharmaceuticals.................................................................................................................................................... 97Deltagen............................................................................................................................................................................... 97Nucleis.................................................................................................................................................................................. 97fermentas............................................................................................................................................................................ 97Diversa.................................................................................................................................................................................. 97Regeneron.Pharmaceuticals.............................................................................................................................................. 97murinus................................................................................................................................................................................ 98Ascenion............................................................................................................................................................................... 98Lexicon.Genetics.................................................................................................................................................................. 99Celliance............................................................................................................................................................................... 99xenogen.biosciences........................................................................................................................................................... 99Ozgene................................................................................................................................................................................. 99biogen.Idec.......................................................................................................................................................................... 99AstraZeneca......................................................................................................................................................................... 99shire.Pharmaceuticals...................................................................................................................................................... 100Celonic................................................................................................................................................................................ 100Genentech.......................................................................................................................................................................... 100GlaxosmithKline................................................................................................................................................................ 100Laboratoires.servier.......................................................................................................................................................... 100TransGenic.......................................................................................................................................................................... 100
Key Financial Data ................................................................................................................................................................ 101Appraisal & Evaluation ......................................................................................................................................................... 101
Platform,.Pipeline,.Products.............................................................................................................................................101Corporate.Environment.....................................................................................................................................................101
COmbINATORx........................................................................................................................................... 103Key Personnel ........................................................................................................................................................................103Company Overview ..............................................................................................................................................................103Milestones ..............................................................................................................................................................................104R&D Pipeline ..........................................................................................................................................................................105
CombinatoRx R&D Pipeline, August 2008 .........................................................................................................................................................................................105Immuno-inflammatory..................................................................................................................................................... 106
CRx-102 .............................................................................................................................................................................................106CRx-139 .............................................................................................................................................................................................106
Pain..................................................................................................................................................................................... 106CRx-170 .............................................................................................................................................................................................106
Dermatology...................................................................................................................................................................... 106CRx-191 .............................................................................................................................................................................................106CRx-197 .............................................................................................................................................................................................106
metabolism........................................................................................................................................................................ 106
Table of Contents
©Espicom Business Intelligence September 2008x
Who’s Developing What in Global Biopharmaceuticals?
CRx-401 ............................................................................................................................................................................................106Other.Research.Programmes........................................................................................................................................... 107
Technologies..........................................................................................................................................................................108Drug.Discovery.Platforms................................................................................................................................................. 108
Patents ....................................................................................................................................................................................108Agreements ...........................................................................................................................................................................109
sosei.................................................................................................................................................................................... 109Accelerate.brain.Cancer.Cure.(AbC2)................................................................................................................................ 109The.National.Institutes.of.Allergy.and.Infectious.Diseases........................................................................................... 109HenKan.Pharmaceutical.Company.................................................................................................................................. 109Angiotech.Pharmaceuticals..............................................................................................................................................110bio*One.Capital..................................................................................................................................................................110fovea.Pharmaceuticals.sA.................................................................................................................................................111Cystic.fibrosis.foundation.Therapeutics.........................................................................................................................111Cure.Huntington's.Disease.Initiative................................................................................................................................111Charley’s.fund/The.Nash.Avery.foundation....................................................................................................................112spinal.muscular.Atrophy.foundation.(smA.foundation)...............................................................................................112sAIC.-.National.Institute.of.Neurological.Disorders.and.stroke.....................................................................................112
Key Financial Data ................................................................................................................................................................ 113Appraisal & Evaluation ......................................................................................................................................................... 114
Platform,.Pipeline,.Products.............................................................................................................................................114Corporate.Environment.....................................................................................................................................................114
DELTANOID.PHARmACEuTICALs...............................................................................................................115Key Personnel ........................................................................................................................................................................ 115Company Overview .............................................................................................................................................................. 115Milestones .............................................................................................................................................................................. 115R&D Pipeline .......................................................................................................................................................................... 116
Osteoporosis.......................................................................................................................................................................1162MD ...................................................................................................................................................................................................116
Agreements ........................................................................................................................................................................... 116Abbott.................................................................................................................................................................................116
Key Financial Data ................................................................................................................................................................ 116Appraisal & Evaluation ......................................................................................................................................................... 117
Platform,.Pipeline,.Products.............................................................................................................................................117Corporate.Environment.....................................................................................................................................................117
DIATOs.........................................................................................................................................................119Key Personnel ........................................................................................................................................................................ 119Company Overview .............................................................................................................................................................. 119Milestones .............................................................................................................................................................................. 120R&D Pipeline .......................................................................................................................................................................... 121
Diatos R&D Pipeline, August 2008 ..................................................................................................................................................................................................... 121Oncology.............................................................................................................................................................................121
DaunoXome.....................................................................................................................................................................................121DTS-301 ............................................................................................................................................................................................122DTS-201 ............................................................................................................................................................................................122DTS-108 ............................................................................................................................................................................................123
Technologies.......................................................................................................................................................................... 123Drug.Development.Platforms...........................................................................................................................................123
Agreements ........................................................................................................................................................................... 124Gilead.sciences...................................................................................................................................................................124macromed...........................................................................................................................................................................124
Table of Contents
©Espicom Business Intelligence xiSeptember 2008
Who’s Developing What in Global Biopharmaceuticals?
medarex...............................................................................................................................................................................124université.catholique.de.Louvain.....................................................................................................................................124Institut.Pasteur...................................................................................................................................................................124servier.................................................................................................................................................................................124OctoPlus.Technologies.......................................................................................................................................................125
Key Financial Data ................................................................................................................................................................ 125Appraisal & Evaluation ......................................................................................................................................................... 125
Platform,.Pipeline,.Products.............................................................................................................................................125Corporate.Environment.....................................................................................................................................................125
EVOTEC....................................................................................................................................................... 127Key Personnel ........................................................................................................................................................................ 127Company Overview .............................................................................................................................................................. 127Milestones .............................................................................................................................................................................. 129R&D Pipeline ..........................................................................................................................................................................130
Evotec R&D Pipeline, August 2008 .....................................................................................................................................................................................................130Central.Nervous.system.....................................................................................................................................................131
EVT 201 .............................................................................................................................................................................................131EVT 101 ............................................................................................................................................................................................131EVT 103 .............................................................................................................................................................................................132EVT 302 ............................................................................................................................................................................................132VR1 Antagonist Programme ........................................................................................................................................................132P2X
3 and P2X
2/3 Antagonist Programme ...................................................................................................................................132
B1 antagonists ................................................................................................................................................................................133H3 antagonists ................................................................................................................................................................................133BACE inhibitors ...............................................................................................................................................................................133
Inflammatory.Disease........................................................................................................................................................133P2X
7 Antagonist Programme .......................................................................................................................................................133
MK2 inhibitors ................................................................................................................................................................................133Oncology.............................................................................................................................................................................133
Hsp90 inhibitors .............................................................................................................................................................................133Bcl-2, Bcl-xL and Mcl-1 inhibitors ................................................................................................................................................134
Technologies..........................................................................................................................................................................134High-throughput.screening.(HTs).Technology.............................................................................................................. 134EVOlution.platform........................................................................................................................................................... 134
Patents ....................................................................................................................................................................................134Agreements ...........................................................................................................................................................................136
boehringer.Ingelheim........................................................................................................................................................136Roche...................................................................................................................................................................................136Cure.Huntingdon’s.Disease.Initiative.(CHDI)...................................................................................................................137Ono.Pharmaceutical...........................................................................................................................................................137Intermune...........................................................................................................................................................................138Takeda.................................................................................................................................................................................138Interprotein.Corporation...................................................................................................................................................138Other.Research.Contracts..................................................................................................................................................138
Key Financial Data ................................................................................................................................................................ 139Appraisal & Evaluation .........................................................................................................................................................140
Platform,.Pipeline,.Products............................................................................................................................................ 140Corporate.Environment.................................................................................................................................................... 140
fIVEPRImE.THERAPEuTICs.........................................................................................................................141Key Personnel ........................................................................................................................................................................ 141Company Overview .............................................................................................................................................................. 141
Table of Contents
©Espicom Business Intelligence September 2008xii
Who’s Developing What in Global Biopharmaceuticals?
Milestones .............................................................................................................................................................................. 142R&D Pipeline .......................................................................................................................................................................... 142
FivePrime Therapeutics R&D Pipeline, August 2008 ..........................................................................................................................................................................142Oncology.............................................................................................................................................................................143
FP-1039 .............................................................................................................................................................................................143FPT040 .............................................................................................................................................................................................143FPA005 ..............................................................................................................................................................................................143FPT069 ..............................................................................................................................................................................................143
metabolism.........................................................................................................................................................................143FPT038 ..............................................................................................................................................................................................143
Cardiology...........................................................................................................................................................................143FPT033/FPT057 ...............................................................................................................................................................................143
Gastrointestinal..................................................................................................................................................................143FPT042/FPT046 ...............................................................................................................................................................................143
Immunology...................................................................................................................................................................... 144FPT025 ..............................................................................................................................................................................................144
Technologies..........................................................................................................................................................................144Drug.Discovery.Platforms................................................................................................................................................. 144
Agreements ...........................................................................................................................................................................145Gene.Logic...........................................................................................................................................................................145biosite..................................................................................................................................................................................145boehringer.Ingelheim........................................................................................................................................................145Centocor/Johnson.&.Johnson............................................................................................................................................145Pfizer....................................................................................................................................................................................145
Key Financial Data ................................................................................................................................................................146Appraisal & Evaluation .........................................................................................................................................................146
Platform,.Pipeline,.Products............................................................................................................................................ 146Corporate.Environment.................................................................................................................................................... 146
GENmAb.A/s............................................................................................................................................... 147Key Personnel ........................................................................................................................................................................ 147Company Overview .............................................................................................................................................................. 147Milestones ..............................................................................................................................................................................148R&D Pipeline ..........................................................................................................................................................................150
Genmab R&D Pipeline, August 2008 .................................................................................................................................................................................................150Oncology.............................................................................................................................................................................151
HuMax-CD4 (zanolimumab) ........................................................................................................................................................151HuMax-CD20 (ofatumumab) ........................................................................................................................................................151HuMax-EGFr (zalutumumab) .......................................................................................................................................................152R1507 ................................................................................................................................................................................................153HuMax-IL8 .......................................................................................................................................................................................153HuMax-CD38 ...................................................................................................................................................................................153HuMax-CD32b .................................................................................................................................................................................153
Autoimmune/Anti-inflammatory.....................................................................................................................................153HuMax-CD20 (ofatumumab) ........................................................................................................................................................153AMG 714 ...........................................................................................................................................................................................154HuMax-IL8 .......................................................................................................................................................................................154HuMax-TAC ......................................................................................................................................................................................154
Neurology...........................................................................................................................................................................155HuMax-CD20 (ofatumumab) ........................................................................................................................................................155
Dermatology.......................................................................................................................................................................155HuMax-IL8 .......................................................................................................................................................................................155
Table of Contents
©Espicom Business Intelligence xiiiSeptember 2008
Who’s Developing What in Global Biopharmaceuticals?
HuMax-TAC ......................................................................................................................................................................................155Respiratory..........................................................................................................................................................................155
Roche 4 .............................................................................................................................................................................................155Virology...............................................................................................................................................................................155
HuMax-HepC ...................................................................................................................................................................................155Transplant.Rejection..........................................................................................................................................................156
HuMax-TAC ......................................................................................................................................................................................156undisclosed.Indications.....................................................................................................................................................156
Roche 2 ............................................................................................................................................................................................156Roche 3 .............................................................................................................................................................................................156
Technologies..........................................................................................................................................................................156Antibody.Discovery.Engine...............................................................................................................................................156
Antibody Centre of Excellence .....................................................................................................................................................156UniBody............................................................................................................................................................................................157
Patents .................................................................................................................................................................................... 157Agreements ........................................................................................................................................................................... 157
Amgen.................................................................................................................................................................................157ACE.biosciences..................................................................................................................................................................157bionomics........................................................................................................................................................................... 158Cytokine.Pharmasciences................................................................................................................................................ 158Ganymed.Pharmaceuticals............................................................................................................................................... 158GlaxosmithKline................................................................................................................................................................ 158medarex..............................................................................................................................................................................159merck.serono......................................................................................................................................................................159Roche...................................................................................................................................................................................159
Key Financial Data ................................................................................................................................................................160Appraisal & Evaluation .........................................................................................................................................................160
Platform,.Pipeline,.Products............................................................................................................................................ 160Corporate.Environment.....................................................................................................................................................161
IDENIx.PHARmACEuTICALs...................................................................................................................... 163Key Personnel ........................................................................................................................................................................163Company Overview ..............................................................................................................................................................163Milestones ..............................................................................................................................................................................164Marketed Products ...............................................................................................................................................................164R&D Pipeline ..........................................................................................................................................................................164
Idenix Pharmaceuticals R&D Pipeline, August 2008 .........................................................................................................................................................................165Virology.............................................................................................................................................................................. 165
IDX184 ..............................................................................................................................................................................................165IDX899 ..............................................................................................................................................................................................165IDX375 ..............................................................................................................................................................................................165IDX136/IDX316 Macrocyclic Protease Inhibitors ......................................................................................................................166
Discontinued Products ........................................................................................................................................................166Valopicitabine/NM283 ..................................................................................................................................................................166
Patents ....................................................................................................................................................................................166Agreements ........................................................................................................................................................................... 167
metabasis.Therapeutics.....................................................................................................................................................167Novartis.Pharma.................................................................................................................................................................167
Key Financial Data ................................................................................................................................................................168Appraisal & Evaluation .........................................................................................................................................................168
Platform,.Pipeline,.Products............................................................................................................................................ 168Corporate.Environment.................................................................................................................................................... 169
Table of Contents
©Espicom Business Intelligence September 2008xiv
Who’s Developing What in Global Biopharmaceuticals?
IKARIA......................................................................................................................................................... 171Key Personnel ........................................................................................................................................................................ 171Company Overview .............................................................................................................................................................. 171Milestones .............................................................................................................................................................................. 172Marketed Products ............................................................................................................................................................... 172R&D Pipeline .......................................................................................................................................................................... 173
Ikaria R&D Pipeline, August 2008 ......................................................................................................................................................................................................173Cardiology...........................................................................................................................................................................173
INOMax.............................................................................................................................................................................................173IK-1001 ..............................................................................................................................................................................................174
Immunology.......................................................................................................................................................................174Covox ................................................................................................................................................................................................174
Other.Research.Programmes............................................................................................................................................174Key Financial Data ................................................................................................................................................................ 174Appraisal & Evaluation ......................................................................................................................................................... 175
Platform,.Pipeline,.Products.............................................................................................................................................175Corporate.Environment.....................................................................................................................................................175
INfINITy.PHARmACEuTICALs................................................................................................................... 177Key Personnel ........................................................................................................................................................................ 177Company Overview .............................................................................................................................................................. 177Milestones .............................................................................................................................................................................. 178R&D Pipeline .......................................................................................................................................................................... 179
Infinity Pharmaceuticals R&D Pipeline, August 2008........................................................................................................................................................................179Oncology.............................................................................................................................................................................179
Retaspimycin ...................................................................................................................................................................................179IPI-493 ..............................................................................................................................................................................................180IPI-926 ...............................................................................................................................................................................................180Bcl-2 Protein Inhibitors..................................................................................................................................................................180
Technologies.......................................................................................................................................................................... 181Diversity.Oriented.synthesis.Technologies.....................................................................................................................181
Patents .................................................................................................................................................................................... 181Agreements ........................................................................................................................................................................... 181
medImmune/AstraZeneca.................................................................................................................................................181Novartis.............................................................................................................................................................................. 182Amgen................................................................................................................................................................................ 182Johnson.&.Johnson........................................................................................................................................................... 182
Key Financial Data ................................................................................................................................................................183Appraisal & Evaluation .........................................................................................................................................................183
Platform,.Pipeline,.Products............................................................................................................................................ 183Corporate.Environment.................................................................................................................................................... 184
INTERCyTEx............................................................................................................................................... 185Key Personnel ........................................................................................................................................................................185Company Overview ..............................................................................................................................................................185Milestones ..............................................................................................................................................................................186R&D Pipeline ..........................................................................................................................................................................186
Intercytex R&D Pipeline, August 2008 ...............................................................................................................................................................................................186Dermatology...................................................................................................................................................................... 186
ICX-PRO (cyzact) .............................................................................................................................................................................186VAVELTA ...........................................................................................................................................................................................187ICX-TRC .............................................................................................................................................................................................187ICX-SKN.............................................................................................................................................................................................188
Table of Contents
©Espicom Business Intelligence xvSeptember 2008
Who’s Developing What in Global Biopharmaceuticals?
Technologies..........................................................................................................................................................................188Agreements ...........................................................................................................................................................................188
baxter.Healthcare............................................................................................................................................................. 188The.Automation.Partnership........................................................................................................................................... 189Armed.forces.Institute.of.Regenerative.medicine......................................................................................................... 189
Key Financial Data ................................................................................................................................................................190Appraisal & Evaluation .........................................................................................................................................................190
Platform,.Pipeline,.Products............................................................................................................................................ 190Corporate.Environment.................................................................................................................................................... 190
IRONWOOD.PHARmACEuTICALs.............................................................................................................. 191Key Personnel ........................................................................................................................................................................ 191Company Overview .............................................................................................................................................................. 191Milestones .............................................................................................................................................................................. 192R&D Pipeline .......................................................................................................................................................................... 192
Ironwood Pharmaceuticals R&D Pipeline, August 2008 ...................................................................................................................................................................192Gastrointestinal..................................................................................................................................................................193
MD-1100/linaclotide ......................................................................................................................................................................193Cardiology...........................................................................................................................................................................193
MD-0727 ..........................................................................................................................................................................................193Agreements ........................................................................................................................................................................... 193
forest.Laboratories............................................................................................................................................................193Key Financial Data ................................................................................................................................................................194Appraisal & Evaluation .........................................................................................................................................................194
Platform,.Pipeline,.Products............................................................................................................................................ 194Corporate.Environment.................................................................................................................................................... 194
KAI.PHARmACEuTICALs............................................................................................................................ 195Key Personnel ........................................................................................................................................................................195Company Overview ..............................................................................................................................................................195Milestones ..............................................................................................................................................................................196R&D Pipeline ..........................................................................................................................................................................196
KAI Pharmaceuticals, August 2008 ....................................................................................................................................................................................................196Cardiology...........................................................................................................................................................................197
KAI-9803 ..........................................................................................................................................................................................197KAI-1455 ...........................................................................................................................................................................................197
Pain.management..............................................................................................................................................................197KAI-1678 ...........................................................................................................................................................................................197Gamma PKC ....................................................................................................................................................................................197
Ophthalmology..................................................................................................................................................................197Beta PKC ..........................................................................................................................................................................................197
Inflammatory.Disease....................................................................................................................................................... 198Theta PKC Inhibition ......................................................................................................................................................................198
Agreements ...........................................................................................................................................................................198sankyo................................................................................................................................................................................ 198bristol-myers.squibb........................................................................................................................................................ 198
Key Financial Data ................................................................................................................................................................198Appraisal & Evaluation .........................................................................................................................................................199
Platform,.Pipeline,.Products............................................................................................................................................ 199Corporate.Environment.................................................................................................................................................... 199
KALyPsys................................................................................................................................................... 201Key Personnel ........................................................................................................................................................................201Company Overview ..............................................................................................................................................................201
Table of Contents
©Espicom Business Intelligence September 2008xvi
Who’s Developing What in Global Biopharmaceuticals?
Milestones ..............................................................................................................................................................................202R&D Pipeline ..........................................................................................................................................................................202
Kalypsys R&D Pipeline, August 2008 .................................................................................................................................................................................................202metabolism........................................................................................................................................................................ 203
KD3010 ............................................................................................................................................................................................ 203KD3020 ............................................................................................................................................................................................ 203
Pain..................................................................................................................................................................................... 203KD7040 ............................................................................................................................................................................................ 203
Oncology............................................................................................................................................................................ 203KD5170 ............................................................................................................................................................................................ 203
Technologies..........................................................................................................................................................................203Agreements ...........................................................................................................................................................................204
merck.&.Co......................................................................................................................................................................... 204CV.Therapeutics................................................................................................................................................................. 204Los.Alamos.National.Laboratory..................................................................................................................................... 204National.Institutes.of.Health............................................................................................................................................ 204NovImmune....................................................................................................................................................................... 205Eidogen-sertanty.............................................................................................................................................................. 205Alcon................................................................................................................................................................................... 205
Key Financial Data ................................................................................................................................................................205Appraisal & Evaluation .........................................................................................................................................................205
Platform,.Pipeline,.Products............................................................................................................................................ 205Corporate.Environment.................................................................................................................................................... 206
KEREOs....................................................................................................................................................... 207Key Personnel ........................................................................................................................................................................207Company Overview ..............................................................................................................................................................207Milestones ..............................................................................................................................................................................208R&D Pipeline ..........................................................................................................................................................................208
Kereos R&D Pipeline, August 2008.....................................................................................................................................................................................................208Oncology............................................................................................................................................................................ 208
KI-0001 ............................................................................................................................................................................................ 208KI-100X ............................................................................................................................................................................................ 208KM-4419 .......................................................................................................................................................................................... 209
Cardiology.......................................................................................................................................................................... 209KI-0002 ........................................................................................................................................................................................... 209KI-1004 ............................................................................................................................................................................................ 209
Technologies..........................................................................................................................................................................209Ligand-Targeted.Emulsion.Technologies........................................................................................................................ 209
Agreements ........................................................................................................................................................................... 210Philips..................................................................................................................................................................................210Lantheus.medical.Imaging.(bristol-myers.squibb.medical.Imaging)...........................................................................210Dow.Chemical.....................................................................................................................................................................210Washington.university......................................................................................................................................................211
Key Financial Data ................................................................................................................................................................ 211Appraisal & Evaluation ......................................................................................................................................................... 211
Platform,.Pipeline,.Products.............................................................................................................................................211Corporate.Environment.....................................................................................................................................................211
mICROmET...................................................................................................................................................213Key Personnel ........................................................................................................................................................................ 213Company Overview .............................................................................................................................................................. 213Milestones .............................................................................................................................................................................. 214
Table of Contents
©Espicom Business Intelligence xviiSeptember 2008
Who’s Developing What in Global Biopharmaceuticals?
R&D Pipeline .......................................................................................................................................................................... 215Micromet R&D Pipeline, August 2008 ...............................................................................................................................................................................................216BiTE Antibody Only Pipeline ...............................................................................................................................................................................................................217
Oncology.............................................................................................................................................................................217MT103/MEDI-538 ............................................................................................................................................................................217Adecatumumab (MT201) ..............................................................................................................................................................218MT293 (D93/TRC093) .................................................................................................................................................................... 220MT110 ...............................................................................................................................................................................................221MT111 ................................................................................................................................................................................................221MT228 (MORAb-028) .....................................................................................................................................................................221bscEphA2xCD3 .............................................................................................................................................................................. 222muS110 ............................................................................................................................................................................................ 222Antibodies targeting CD33 and MCSP ...................................................................................................................................... 222
Inflammatory/Autoimmune.Diseases............................................................................................................................. 222MT203 .............................................................................................................................................................................................. 222MT204 .............................................................................................................................................................................................. 223
Technologies..........................................................................................................................................................................223biTE.(bispecific.T-Cell.Engagers).Technology.................................................................................................................. 223single.Chain.Antibodies.................................................................................................................................................... 223
Patents ....................................................................................................................................................................................224Agreements ...........................................................................................................................................................................224
Enzon.Pharmaceuticals..................................................................................................................................................... 224Abbott,.Alligator.bioscience.Ab,.Haptogen.and.A.N.Other........................................................................................... 224Cambridge.Antibody.Technology.(CAT).......................................................................................................................... 224EsbATech.AG...................................................................................................................................................................... 225medImmune...................................................................................................................................................................... 225serono................................................................................................................................................................................ 226EvoGenix.Pty...................................................................................................................................................................... 226Novuspharma.spA............................................................................................................................................................. 226TRACON.Pharmaceuticals................................................................................................................................................. 227morphotek......................................................................................................................................................................... 227Nycomed............................................................................................................................................................................ 227university.of.southern.California.................................................................................................................................... 227Applied.molecular.Evolution/Eli.Lilly.............................................................................................................................. 228Arizeke.Pharmaceuticals.................................................................................................................................................. 228Antigenics.......................................................................................................................................................................... 228Viventia.barbados............................................................................................................................................................. 228
Key Financial Data ................................................................................................................................................................229Appraisal & Evaluation .........................................................................................................................................................230
Platform,.Pipeline,.Products............................................................................................................................................ 230Corporate.Environment.................................................................................................................................................... 230
mOLECuLAR.INsIGHT.PHARmACEuTICALs.............................................................................................. 231Key Personnel ........................................................................................................................................................................231Company Overview ..............................................................................................................................................................231Milestones ..............................................................................................................................................................................232R&D Pipeline ..........................................................................................................................................................................233
Molecular Insight R&D Pipeline, August 2008 ...................................................................................................................................................................................233Oncology............................................................................................................................................................................ 233
Azedra ..............................................................................................................................................................................................233Onalta .............................................................................................................................................................................................. 234Solazed ............................................................................................................................................................................................ 234
Table of Contents
©Espicom Business Intelligence September 2008xviii
Who’s Developing What in Global Biopharmaceuticals?
Trofex ............................................................................................................................................................................................... 234Cardiology.......................................................................................................................................................................... 235
Zemiva ............................................................................................................................................................................................ 235MIP-190............................................................................................................................................................................................ 235
Neurology.......................................................................................................................................................................... 235MIP-170D ......................................................................................................................................................................................... 235
Technologies..........................................................................................................................................................................236ultratrace.Technology...................................................................................................................................................... 236sAAC.Technology............................................................................................................................................................... 236sAACQ.Technology............................................................................................................................................................ 236Nanotrace.Discovery......................................................................................................................................................... 236
Patents ....................................................................................................................................................................................236Agreements ...........................................................................................................................................................................237
bayer.schering.Pharma..................................................................................................................................................... 237Novartis.Pharma................................................................................................................................................................ 237
Key Financial Data ................................................................................................................................................................238Appraisal & Evaluation .........................................................................................................................................................238
Platform,.Pipeline,.Products............................................................................................................................................ 238Corporate.Environment.................................................................................................................................................... 239
NEuROmED.PHARmACEuTICALs.............................................................................................................. 241Key Personnel ........................................................................................................................................................................ 241Company Overview .............................................................................................................................................................. 241Milestones ..............................................................................................................................................................................242R&D Pipeline ..........................................................................................................................................................................243
Neuromed Pharmaceuticals Pipeline, August 2008 ..........................................................................................................................................................................243Pain..................................................................................................................................................................................... 243
NMED-160 ........................................................................................................................................................................................243NMED-1077 .....................................................................................................................................................................................243Others .............................................................................................................................................................................................. 244
Other.Indications............................................................................................................................................................... 244Agreements ...........................................................................................................................................................................244
merck.&.Co......................................................................................................................................................................... 244Key Financial Data ................................................................................................................................................................245Appraisal & Evaluation .........................................................................................................................................................245
Platform,.Pipeline,.Products............................................................................................................................................ 245Corporate.Environment.................................................................................................................................................... 245
NOVExEL.................................................................................................................................................... 247Key Personnel ........................................................................................................................................................................247Company Overview ..............................................................................................................................................................247Milestones ..............................................................................................................................................................................248R&D Pipeline ..........................................................................................................................................................................248
Novexel R&D Pipeline, August 2008 ..................................................................................................................................................................................................248Antibacterial...................................................................................................................................................................... 248
NXL103 ............................................................................................................................................................................................. 248NXL101 ..............................................................................................................................................................................................249NXL104 ..............................................................................................................................................................................................249NXL105 .............................................................................................................................................................................................249
Antifungal.......................................................................................................................................................................... 249NXL201 .............................................................................................................................................................................................249
Agreements ...........................................................................................................................................................................250Indevus.Pharmaceuticals.................................................................................................................................................. 250
Table of Contents
©Espicom Business Intelligence xixSeptember 2008
Who’s Developing What in Global Biopharmaceuticals?
forest.Laboratories........................................................................................................................................................... 250Key Financial Data ................................................................................................................................................................250Appraisal & Evaluation .........................................................................................................................................................250
Platform,.Pipeline,.Products............................................................................................................................................ 250Corporate.Environment.................................................................................................................................................... 251
NPs.PHARmACEuTICALs........................................................................................................................... 253Key Personnel ........................................................................................................................................................................253Company Overview ..............................................................................................................................................................253Milestones ..............................................................................................................................................................................255R&D Pipeline ..........................................................................................................................................................................256
NPS Pharmaceuticals R&D Pipeline, August 2008 .............................................................................................................................................................................256Gastrointestinal................................................................................................................................................................. 257
GATTEX ............................................................................................................................................................................................ 257musculoskeletal................................................................................................................................................................. 257
PREOS/Preotact ............................................................................................................................................................................. 257calcilytics ......................................................................................................................................................................................... 258
Central.Nervous.system.................................................................................................................................................... 258NPSP156 .......................................................................................................................................................................................... 258
metabolism........................................................................................................................................................................ 258NPSP558 (parathyroid hormone 1-84 [rDNA origin] injection) ............................................................................................ 258
Renal................................................................................................................................................................................... 258Cinacalcet HCl ................................................................................................................................................................................ 258
Patents ....................................................................................................................................................................................259Agreements ...........................................................................................................................................................................259
Amgen................................................................................................................................................................................ 259Kirin.Pharma...................................................................................................................................................................... 260Nycomed............................................................................................................................................................................ 260DRI.Capital...........................................................................................................................................................................261GlaxosmithKline.................................................................................................................................................................261Janssen............................................................................................................................................................................... 262AstraZeneca....................................................................................................................................................................... 262Ortho-mcNeil.Pharmaceuticals........................................................................................................................................ 262
Key Financial Data ................................................................................................................................................................263Appraisal & Evaluation .........................................................................................................................................................263
Platform,.Pipeline,.Products............................................................................................................................................ 263Corporate.Environment.................................................................................................................................................... 263
OPTImER.PHARmACEuTICALs.................................................................................................................. 265Key Personnel ........................................................................................................................................................................265Company Overview ..............................................................................................................................................................265Milestones ..............................................................................................................................................................................266R&D Pipeline ..........................................................................................................................................................................267
Optimer Pharmaceuticals R&D Pipeline, August 2008 ......................................................................................................................................................................267Antibacterial...................................................................................................................................................................... 267
OPT-80 ..............................................................................................................................................................................................267Prulifloxacin (OPT-99) ................................................................................................................................................................... 268OPT-1068/CEM-101 ........................................................................................................................................................................ 269
musculoskeletal................................................................................................................................................................. 269OPT-88 ............................................................................................................................................................................................. 269
Oncology............................................................................................................................................................................ 269OPT-822/OPT-821 .......................................................................................................................................................................... 269
Technologies..........................................................................................................................................................................270
Table of Contents
©Espicom Business Intelligence September 2008xx
Who’s Developing What in Global Biopharmaceuticals?
Drug.Discovery.Platform.................................................................................................................................................. 270Patents ....................................................................................................................................................................................270Agreements ...........................................................................................................................................................................271
C&O.Pharmaceutical.Technology.(Holdings).................................................................................................................. 271Par.Pharmaceutical............................................................................................................................................................ 271biocon................................................................................................................................................................................. 271Nippon.shinyaku............................................................................................................................................................... 271sloan-Kettering.Institute.for.Cancer.Research............................................................................................................... 272Cempra.Pharmaceuticals.................................................................................................................................................. 272The.scripps.Research.Institute......................................................................................................................................... 273Inc.Research....................................................................................................................................................................... 273National.Institute.of.Allergy.and.Infectious.Diseases.................................................................................................... 273
Key Financial Data ................................................................................................................................................................ 274Appraisal & Evaluation ......................................................................................................................................................... 274
Platform,.Pipeline,.Products.............................................................................................................................................274Corporate.Environment.....................................................................................................................................................274
PALATIN.TECHNOLOGIEs........................................................................................................................... 275Key Personnel ........................................................................................................................................................................275Company Overview ..............................................................................................................................................................275Milestones ..............................................................................................................................................................................276R&D Pipeline ..........................................................................................................................................................................277
Palatin Technologies R&D Pipeline, August 2008 ..............................................................................................................................................................................277Cardiology.......................................................................................................................................................................... 277
Bremelanotide ................................................................................................................................................................................277PL-6983 .............................................................................................................................................................................................278Natriuretic Receptor Compounds/PL-3994 ...............................................................................................................................278
metabolism........................................................................................................................................................................ 278Melanocortin-based Therapeutics .............................................................................................................................................278
Imaging/Diagnosis............................................................................................................................................................ 278NeutroSpec ......................................................................................................................................................................................278
Technologies..........................................................................................................................................................................279Drug.Development.Platforms.......................................................................................................................................... 279
MIDAS Drug Development Platform ..........................................................................................................................................279NeutroSpec ......................................................................................................................................................................................279
Patents ....................................................................................................................................................................................279Agreements ...........................................................................................................................................................................280
AstraZeneca....................................................................................................................................................................... 280mallinckrodt...................................................................................................................................................................... 280
Key Financial Data ................................................................................................................................................................281Appraisal & Evaluation .........................................................................................................................................................281
Platform,.Pipeline,.Products............................................................................................................................................ 281Corporate.Environment.................................................................................................................................................... 282
PHARmAmAR............................................................................................................................................. 283Key Personnel ........................................................................................................................................................................283Company Overview ..............................................................................................................................................................283Milestones ..............................................................................................................................................................................284R&D Pipeline ..........................................................................................................................................................................284
PharmaMar R&D Pipeline, August 2008 ...........................................................................................................................................................................................284Oncology............................................................................................................................................................................ 285
Yondelis (trabectedin) .................................................................................................................................................................. 285Aplidin (plitidepsin) ...................................................................................................................................................................... 286
Table of Contents
©Espicom Business Intelligence xxiSeptember 2008
Who’s Developing What in Global Biopharmaceuticals?
PM02734 ......................................................................................................................................................................................... 287Kahalalide F ................................................................................................................................................................................... 287Zalypsis............................................................................................................................................................................................ 287Thiocoraline ................................................................................................................................................................................... 288Variolins .......................................................................................................................................................................................... 288Lamellarins ..................................................................................................................................................................................... 288
Dermatology...................................................................................................................................................................... 288Kahalalide F ................................................................................................................................................................................... 288
Agreements ...........................................................................................................................................................................288Johnson.&.Johnson........................................................................................................................................................... 288Innovex............................................................................................................................................................................... 288swedish.Orphan.International......................................................................................................................................... 288Genesis.Pharma................................................................................................................................................................. 288Cenit-Nanopharma.Consortium...................................................................................................................................... 289
Key Financial Data ................................................................................................................................................................289Appraisal & Evaluation .........................................................................................................................................................290
Platform,.Pipeline,.Products............................................................................................................................................ 290Corporate.Environment.................................................................................................................................................... 290
PRANA.bIOTECHNOLOGy.......................................................................................................................... 291Key Personnel ........................................................................................................................................................................291Company Overview ..............................................................................................................................................................291Milestones ..............................................................................................................................................................................293R&D Pipeline ..........................................................................................................................................................................294
Prana Biotechnology R&D Pipeline, August 2008 .............................................................................................................................................................................294Central.Nervous.system.................................................................................................................................................... 294
PBT2 ................................................................................................................................................................................................. 294Drug Candidate ............................................................................................................................................................................. 295Amyloid-inhibiting compounds ................................................................................................................................................. 295
Immunotherapy................................................................................................................................................................ 296MAbs against Abeta ...................................................................................................................................................................... 296
Oncology............................................................................................................................................................................ 296PBT1/others .................................................................................................................................................................................... 296
Ophthalmology................................................................................................................................................................. 296MPAC Compounds ........................................................................................................................................................................ 296
Discontinued Products ........................................................................................................................................................297Central.Nervous.system.................................................................................................................................................... 297
PBT1 (Clioquinol) ........................................................................................................................................................................... 297Patents ....................................................................................................................................................................................297Agreements ...........................................................................................................................................................................298
schering.AG........................................................................................................................................................................ 298Australian.Industry.Research.and.Development.board................................................................................................ 298
Key Financial Data ................................................................................................................................................................299Appraisal & Evaluation .........................................................................................................................................................299
Platform,.Pipeline,.Products............................................................................................................................................ 299Corporate.Environment.................................................................................................................................................... 300
REPLIDyNE................................................................................................................................................. 301Key Personnel ........................................................................................................................................................................301Company Overview ..............................................................................................................................................................301Milestones ..............................................................................................................................................................................302R&D Pipeline ..........................................................................................................................................................................303
Replidyne R&D Pipeline, August 2008 ...............................................................................................................................................................................................303
Table of Contents
©Espicom Business Intelligence September 2008xxii
Who’s Developing What in Global Biopharmaceuticals?
Antibacterial...................................................................................................................................................................... 303Faropenem medoxomil ............................................................................................................................................................... 303REP3123/REP8839 ......................................................................................................................................................................... 305DNA Replication Inhibitors Programme ................................................................................................................................... 306
Patents ....................................................................................................................................................................................306Agreements ...........................................................................................................................................................................307
forest.Laboratories........................................................................................................................................................... 307Asubio.Pharma.................................................................................................................................................................. 307
Key Financial Data ................................................................................................................................................................308Appraisal & Evaluation .........................................................................................................................................................309
Platform,.Pipeline,.Products............................................................................................................................................ 309Corporate.Environment.................................................................................................................................................... 309
s*bIO............................................................................................................................................................311Key Personnel ........................................................................................................................................................................ 311Company Overview .............................................................................................................................................................. 311Milestones .............................................................................................................................................................................. 312R&D Pipeline .......................................................................................................................................................................... 312
Clinical.Trials.......................................................................................................................................................................312HDAC .................................................................................................................................................................................................312Kinase Programme ........................................................................................................................................................................312S*BIO R&D Pipeline, 2008 .................................................................................................................................................................................................................. 313
Technology ............................................................................................................................................................................ 313Agreements ........................................................................................................................................................................... 313
A*sTAR.................................................................................................................................................................................313Genome.Institute.of.singapore.........................................................................................................................................314Karolinska.Institutet..........................................................................................................................................................314National.university.Hospital,.singapore.........................................................................................................................314
Key Financial Data ................................................................................................................................................................ 314Appraisal & Evaluation ......................................................................................................................................................... 314
Platform,.Pipeline,.Products.............................................................................................................................................314Corporate.Environment.....................................................................................................................................................314
sOsEI............................................................................................................................................................315Key Personnel ........................................................................................................................................................................ 315Company Overview .............................................................................................................................................................. 315Milestones .............................................................................................................................................................................. 317R&D Pipeline .......................................................................................................................................................................... 317
Sosei R&D Pipeline, August 2008 ....................................................................................................................................................................................................... 317Respiratory.system............................................................................................................................................................318
NVA237 .............................................................................................................................................................................................318QVA149 .............................................................................................................................................................................................318
Oncology.............................................................................................................................................................................319AD923 ...............................................................................................................................................................................................319
Central.Nervous.system.....................................................................................................................................................319AD337 ...............................................................................................................................................................................................319SD118 ................................................................................................................................................................................................319
Inflammation.and.Immunology...................................................................................................................................... 320SD726 ................................................................................................................................................................................................320SD208 ................................................................................................................................................................................................320
Women’s.Healthcare......................................................................................................................................................... 320SOH-075 ...........................................................................................................................................................................................320
Agreements ...........................................................................................................................................................................320
Table of Contents
©Espicom Business Intelligence xxiiiSeptember 2008
Who’s Developing What in Global Biopharmaceuticals?
mundipharma.................................................................................................................................................................... 320sandoz.................................................................................................................................................................................321CombinatoRx......................................................................................................................................................................321
Key Financial Data ................................................................................................................................................................321Appraisal & Evaluation .........................................................................................................................................................322
Platform,.Pipeline,.Products............................................................................................................................................ 322Corporate.Environment.................................................................................................................................................... 322
sPEEDEL.PHARmACEuTICALs................................................................................................................... 323Key Personnel ........................................................................................................................................................................323Company Overview ..............................................................................................................................................................323Milestones ..............................................................................................................................................................................325R&D Pipeline ..........................................................................................................................................................................327
Speedel R&D Pipeline, August 2008 ..................................................................................................................................................................................................327Cardiology.......................................................................................................................................................................... 328
SPP100 (aliskiren,Tekturna, Rasilez) ...........................................................................................................................................328SPP200 (pegmusirudin) ................................................................................................................................................................329SPP301 (avosentan) ........................................................................................................................................................................329SPP600 .............................................................................................................................................................................................330SPP635 ..............................................................................................................................................................................................330SPP676 ..............................................................................................................................................................................................330SPP800 Series ..................................................................................................................................................................................330SPP1100 Series ................................................................................................................................................................................331SPP2000 Series ...............................................................................................................................................................................331
Agreements ........................................................................................................................................................................... 331Locus.Pharmaceuticals......................................................................................................................................................331Novartis...............................................................................................................................................................................331Roche.................................................................................................................................................................................. 332Abbott.Laboratories.......................................................................................................................................................... 332
Key Financial Data ................................................................................................................................................................333Appraisal & Evaluation .........................................................................................................................................................333
Platform,.Pipeline,.Products............................................................................................................................................ 333Corporate.Environment.................................................................................................................................................... 333
syNTA.PHARmACEuTICALs....................................................................................................................... 335Key Personnel ........................................................................................................................................................................335Company Overview ..............................................................................................................................................................335Milestones ..............................................................................................................................................................................337R&D Pipeline ..........................................................................................................................................................................338
Synta Pharmaceuticals R&D Pipeline, August 2008 ..........................................................................................................................................................................338Oncology............................................................................................................................................................................ 338
STA-4783 (elesclomol) ...................................................................................................................................................................338STA-9090 ..........................................................................................................................................................................................339STA-9584 ..........................................................................................................................................................................................339STA-5312 ...........................................................................................................................................................................................339
Inflammatory.Disease....................................................................................................................................................... 340STA-5326 (apilimod mesylate) .................................................................................................................................................... 340Crohn’s Disease .............................................................................................................................................................................. 340Rheumatoid Arthritis ................................................................................................................................................................... 340Common Variable Immunodeficiency ...................................................................................................................................... 340Psoriasis........................................................................................................................................................................................... 340CRAC ion channel inhibitor ......................................................................................................................................................... 340
Technologies..........................................................................................................................................................................341
Table of Contents
©Espicom Business Intelligence September 2008xxiv
Who’s Developing What in Global Biopharmaceuticals?
Chemical.Library................................................................................................................................................................ 341screening.Assays............................................................................................................................................................... 341In.vivo.Testing.Capabilities............................................................................................................................................... 341Chemistry.Capabilities...................................................................................................................................................... 341Target.Elucidation............................................................................................................................................................. 341
Patents ....................................................................................................................................................................................341Agreements ...........................................................................................................................................................................342
GlaxosmithKline................................................................................................................................................................ 342Key Financial Data ................................................................................................................................................................343Appraisal & Evaluation .........................................................................................................................................................343
Platform,.Pipeline,.Products............................................................................................................................................ 343Corporate.Environment.................................................................................................................................................... 344
syNTAxIN................................................................................................................................................... 345Key Personnel ........................................................................................................................................................................345Company Overview ..............................................................................................................................................................345Milestones ..............................................................................................................................................................................346R&D Pipeline ..........................................................................................................................................................................346
Syntaxin R&D Pipeline, August 2008 .................................................................................................................................................................................................346Pain..................................................................................................................................................................................... 347
Un-named Product ........................................................................................................................................................................347Respiratory......................................................................................................................................................................... 347
SYN187 .............................................................................................................................................................................................347Other................................................................................................................................................................................... 347
Endocrinology Products ...............................................................................................................................................................347Obesity Products ........................................................................................................................................................................... 348Nerve Disorder Products ............................................................................................................................................................. 348
Agreements ...........................................................................................................................................................................348Allergan.............................................................................................................................................................................. 348
Key Financial Data ................................................................................................................................................................348Appraisal & Evaluation .........................................................................................................................................................348
Platform,.Pipeline,.Products............................................................................................................................................ 348Corporate.Environment.................................................................................................................................................... 348
TAKARA.bIO................................................................................................................................................ 349Key Personnel ........................................................................................................................................................................349Company Overview ..............................................................................................................................................................349Milestones ..............................................................................................................................................................................350R&D Pipeline ..........................................................................................................................................................................350
Oncology............................................................................................................................................................................ 350HSV-TK gene therapies ................................................................................................................................................................ 350T-cell receptor (TCR) gene therapy .............................................................................................................................................351Cancer Immunotherapy ...............................................................................................................................................................351Cancer Immunity Reconstruction Therapy ...............................................................................................................................351
Virology.............................................................................................................................................................................. 352VRX496 ............................................................................................................................................................................................352MazF Gene Therapy .......................................................................................................................................................................352
Technologies..........................................................................................................................................................................352Research.Reagents.and.scientific.Instruments.............................................................................................................. 352Contract.Research.services.............................................................................................................................................. 353
Agreements ...........................................................................................................................................................................353InVivoscribe.Technologies............................................................................................................................................... 353memorial.sloan-Kettering.Cancer.Center....................................................................................................................... 353
Table of Contents
©Espicom Business Intelligence xxvSeptember 2008
Who’s Developing What in Global Biopharmaceuticals?
Peter.macCallum.Cancer.Centre....................................................................................................................................... 354Green.Cross.Corporation.................................................................................................................................................. 354New.England.biolabs........................................................................................................................................................ 354Transgenomic..................................................................................................................................................................... 354Kemp.biotechnologies...................................................................................................................................................... 354Tianjin.medical.university................................................................................................................................................ 354
Key Financial Data ................................................................................................................................................................355Appraisal & Evaluation .........................................................................................................................................................356
Platform,.Pipeline,.Products............................................................................................................................................ 356Corporate.Environment.................................................................................................................................................... 356
THERAVANCE............................................................................................................................................. 357Key Personnel ........................................................................................................................................................................357Company Overview ..............................................................................................................................................................357Milestones ..............................................................................................................................................................................358R&D Pipeline ..........................................................................................................................................................................359
Theravance R&D Pipeline, August 2008 ............................................................................................................................................................................................359Antibacterial...................................................................................................................................................................... 359
Telavancin ........................................................................................................................................................................................359TD-1792 ........................................................................................................................................................................................... 360
Respiratory..........................................................................................................................................................................361GW642444 .......................................................................................................................................................................................361GW685698 .......................................................................................................................................................................................361GSK159797 .......................................................................................................................................................................................361GSK1160724 .................................................................................................................................................................................... 362GSK656398...................................................................................................................................................................................... 362GSK961081 ...................................................................................................................................................................................... 362
Gastrointestinal................................................................................................................................................................. 362TD-5108 ........................................................................................................................................................................................... 363TD-2749 ........................................................................................................................................................................................... 363TD-6301 ........................................................................................................................................................................................... 363
Patents ....................................................................................................................................................................................363Agreements ...........................................................................................................................................................................364
Astellas............................................................................................................................................................................... 364GlaxosmithKline................................................................................................................................................................ 364AstraZeneca....................................................................................................................................................................... 366
Key Financial Data ................................................................................................................................................................366Appraisal & Evaluation .........................................................................................................................................................366
Platform,.Pipeline,.Products............................................................................................................................................ 366Corporate.Environment.................................................................................................................................................... 367
TRANZymE.PHARmA................................................................................................................................. 369Key Personnel ........................................................................................................................................................................369Company Overview ..............................................................................................................................................................369Milestones ..............................................................................................................................................................................370R&D Pipeline ..........................................................................................................................................................................370
Tranzyme Pharma R&D Pipeline, August 2008 .................................................................................................................................................................................370Gastrointestinal................................................................................................................................................................. 371
TZP-101 .............................................................................................................................................................................................371TZP-102 .............................................................................................................................................................................................372TZP-201 .............................................................................................................................................................................................372TZP-301 ............................................................................................................................................................................................372
Technologies..........................................................................................................................................................................372
Table of Contents
©Espicom Business Intelligence September 2008xxvi
Who’s Developing What in Global Biopharmaceuticals?
Drug.Discovery.Platform.................................................................................................................................................. 372Macrocyclic Template Chemistry (MATCH) ................................................................................................................................372
Patents ....................................................................................................................................................................................373Agreements ...........................................................................................................................................................................373
Neokimia/Trimeris............................................................................................................................................................ 373Key Financial Data ................................................................................................................................................................373Appraisal & Evaluation .........................................................................................................................................................373
Platform,.Pipeline,.Products............................................................................................................................................ 373Corporate.Environment.....................................................................................................................................................374
TRImERIs.................................................................................................................................................... 375Key Personnel ........................................................................................................................................................................375Company Overview ..............................................................................................................................................................375Milestones ..............................................................................................................................................................................377Marketed Products ...............................................................................................................................................................378
Virology.............................................................................................................................................................................. 378FUZEON ............................................................................................................................................................................................378
R&D Pipeline ..........................................................................................................................................................................379Virology.............................................................................................................................................................................. 379
FUZEON ............................................................................................................................................................................................379TRI-1144 ........................................................................................................................................................................................... 380
Patents ....................................................................................................................................................................................381Agreements ...........................................................................................................................................................................381
Roche.................................................................................................................................................................................. 381Array.biopharma............................................................................................................................................................... 382Neokimia/Tranzyme......................................................................................................................................................... 382Chembridge.Research.Laboratories................................................................................................................................ 383New.york.blood.Center..................................................................................................................................................... 383
Key Financial Data ................................................................................................................................................................384Appraisal & Evaluation .........................................................................................................................................................384
Platform,.Pipeline,.Products............................................................................................................................................ 384Corporate.Environment.................................................................................................................................................... 385
TRubION.PHARmACEuTICALs.................................................................................................................. 387Key Personnel ........................................................................................................................................................................387Company Overview ..............................................................................................................................................................387Milestones ..............................................................................................................................................................................388R&D Pipeline ..........................................................................................................................................................................389
Trubion Pharmaceuticals R&D Pipeline, August 2008 .......................................................................................................................................................................389Autoimmune/Inflammatory.Diseases............................................................................................................................. 389
TRU-015 ........................................................................................................................................................................................... 389SBI-087 ............................................................................................................................................................................................ 390
Oncology............................................................................................................................................................................ 390TRU-015 ........................................................................................................................................................................................... 390TRU-016 ............................................................................................................................................................................................391
Technologies..........................................................................................................................................................................391Product.Engine.................................................................................................................................................................. 391
Patents ....................................................................................................................................................................................391Agreements ...........................................................................................................................................................................392
Wyeth................................................................................................................................................................................. 392Key Financial Data ................................................................................................................................................................393Appraisal & Evaluation .........................................................................................................................................................393
Platform,.Pipeline,.Products............................................................................................................................................ 393
Table of Contents
©Espicom Business Intelligence xxviiSeptember 2008
Who’s Developing What in Global Biopharmaceuticals?
Corporate.Environment.................................................................................................................................................... 393VIROPHARmA............................................................................................................................................. 395
Key Personnel ........................................................................................................................................................................395Company Overview ..............................................................................................................................................................395Milestones ..............................................................................................................................................................................397Marketed Products ...............................................................................................................................................................398
Antibacterial...................................................................................................................................................................... 398Vancocin .......................................................................................................................................................................................... 398
R&D Pipeline ..........................................................................................................................................................................398ViroPharma R&D Pipeline, August 2008 ...........................................................................................................................................................................................398
Virology.............................................................................................................................................................................. 399Maribavir (CAMVIA) ...................................................................................................................................................................... 399CDI Programme ............................................................................................................................................................................. 400
Anti-inflammatory............................................................................................................................................................ 400C1 inhibitor (human) ..................................................................................................................................................................... 400
Discontinued Products ........................................................................................................................................................400Virology.............................................................................................................................................................................. 400
Picovir (Pleconaril)......................................................................................................................................................................... 400Hepatitis C Candidates ................................................................................................................................................................. 400HCV371 ............................................................................................................................................................................................ 401HCV-086 .......................................................................................................................................................................................... 401HCV-796........................................................................................................................................................................................... 401
Patents ....................................................................................................................................................................................402Agreements ...........................................................................................................................................................................402
GlaxosmithKline................................................................................................................................................................ 402sanofi-synthélabo/sanofi-aventis................................................................................................................................... 402schering-Plough................................................................................................................................................................ 404Eli.Lilly................................................................................................................................................................................. 404Wyeth................................................................................................................................................................................. 404
Key Financial Data ................................................................................................................................................................406Appraisal & Evaluation .........................................................................................................................................................406
Platform,.Pipeline,.Products............................................................................................................................................ 406Corporate.Environment.................................................................................................................................................... 407
WILEx.......................................................................................................................................................... 409Key Personnel ........................................................................................................................................................................409Company Overview ..............................................................................................................................................................409Milestones .............................................................................................................................................................................. 411R&D Pipeline .......................................................................................................................................................................... 413
WILEX R&D Pipeline, August 2008 ..................................................................................................................................................................................................... 413Oncology.............................................................................................................................................................................414
WX-G250 and WX-G250RIT (RENCAREX) ...................................................................................................................................414WX-UK1 ............................................................................................................................................................................................414K931 ..................................................................................................................................................................................................415WX-671 (MESUPRON) ....................................................................................................................................................................415CA9-SCAN (REDECTANE) ...............................................................................................................................................................416WX-77X Series .................................................................................................................................................................................416
Patents .................................................................................................................................................................................... 416Agreements ........................................................................................................................................................................... 417
Centocor..............................................................................................................................................................................417bayer....................................................................................................................................................................................417Vu.university.medical.Center.Amsterdam......................................................................................................................417
Table of Contents
©Espicom Business Intelligence September 2008xxviii
Who’s Developing What in Global Biopharmaceuticals?
fox.Chase.Cancer.Center....................................................................................................................................................417Esteve..................................................................................................................................................................................418IbA.molecular......................................................................................................................................................................418
Key Financial Data ................................................................................................................................................................ 419Appraisal & Evaluation ......................................................................................................................................................... 419
Platform,.Pipeline,.Products.............................................................................................................................................419Corporate.Environment.................................................................................................................................................... 420
xENCOR...................................................................................................................................................... 421Key Personnel ........................................................................................................................................................................421Company Overview ..............................................................................................................................................................421Milestones ..............................................................................................................................................................................422R&D Pipeline ..........................................................................................................................................................................422
Xencor R&D Pipeline, August 2008 ....................................................................................................................................................................................................422Inflammatory.Disease....................................................................................................................................................... 422
XPro1595 ..........................................................................................................................................................................................423Oncology............................................................................................................................................................................ 423
XmAb2513 .......................................................................................................................................................................................423Oncology/Inflammatory.Disease..................................................................................................................................... 423
XmAb5574 .......................................................................................................................................................................................423XmAb5871 .......................................................................................................................................................................................424XmAb5485 ......................................................................................................................................................................................424
Technologies..........................................................................................................................................................................424Protein.Design.Automation............................................................................................................................................. 424xPro.................................................................................................................................................................................... 425
XmAb technology ..........................................................................................................................................................................425ImmunoPDA ....................................................................................................................................................................................425
Patents ....................................................................................................................................................................................426Agreements ...........................................................................................................................................................................426
Caltech................................................................................................................................................................................ 426Torrey.mesa.Research.Institute........................................................................................................................................ 426Protein.Design.Labs.......................................................................................................................................................... 426Eli.Lilly................................................................................................................................................................................. 427Genentech.......................................................................................................................................................................... 427Chugai.Pharmaceutical..................................................................................................................................................... 427Centocor............................................................................................................................................................................. 427medImmune...................................................................................................................................................................... 427Roche.................................................................................................................................................................................. 428boehringer.Ingelheim....................................................................................................................................................... 428Human.Genome.sciences................................................................................................................................................. 428
Key Financial Data ................................................................................................................................................................428Appraisal & Evaluation .........................................................................................................................................................428
Platform,.Pipeline,.Products............................................................................................................................................ 428Corporate.Environment.................................................................................................................................................... 429
EsPICOm.ANALysIs.................................................................................................................................... 433Winners & Losers ..................................................................................................................................................................433Biopharmaceutical Company R&D Pipelines ..................................................................................................................434
Phase.III.Drug.Candidates................................................................................................................................................. 435Phase III Drug Candidates ..................................................................................................................................................................................................................435
Methodology .........................................................................................................................................................................436Company.Ratings.............................................................................................................................................................. 436
Section Name